COVID-19 testing propelled a Canadian biotech stock sharply higher Monday. Here’s some small stocks making big moves on Monday, April 20, 2020 (as of 4 pm EST):
StageZero Life Sciences, Ltd. (TSX:SZLS), a Canadian biotech stock, climbed 14% to $0.08 on Monday after announcing that it is initiating testing for the COVID-19 virus from its CLIA-certified lab in Richmond, Virginia. The Company added that it will offer both the PCR-based nucleic acid tests as well qualitative antibody testing.
As well, shares of The Alkaline Water Company Inc. (TSXV:WTER) surged 30% to $1.59 as the producer of bottled alkaline water and CBD-infused products said it has increased production capacity significantly to meet demand.
YDX Innovation Corp. (TSXV:YDX), meanwhile, reported that it has finished the development and implementation of the new Customer Experience Center for the Brazilian-based aerospace manufacturer, Embraer. YDX Innovation stock popped 83% to $0.165 following the announcement.
Finally, Fosterville South Exploration Ltd. (TSXV:FSX) shares rose 10% to $1.32 after the gold junior announced that it has agreed to acquire three gold projects, the Timor Project, the Avoca Project and the Moormbool Project, from Mercator Gold Australia Pty Limited in consideration for A$500,000 plus A$1 for every one ounce of gold or gold equivalent of Measured resource, Indicated resource or Inferred resource within one or more of the tenements comprising the Gold Projects, which payment shall not exceed a total of A$1 million.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
StageZero Life Sciences, Ltd. (TSX:SZLS), a Canadian biotech stock, climbed 14% to $0.08 on Monday after announcing that it is initiating testing for the COVID-19 virus from its CLIA-certified lab in Richmond, Virginia. The Company added that it will offer both the PCR-based nucleic acid tests as well qualitative antibody testing.
, sharply higher on Monday.){kind=link}